{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:13:14Z","timestamp":1778818394610,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":4572,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["M01-RR-00037"],"award-info":[{"award-number":["M01-RR-00037"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA92302"],"award-info":[{"award-number":["R01CA92302"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007812","name":"University of Washington","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002985","name":"Hext Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002985","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1016\/j.ymthe.2003.12.011","type":"journal-article","created":{"date-parts":[[2004,3,6]],"date-time":"2004-03-06T06:42:33Z","timestamp":1078555353000},"page":"577-586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Cellular Immunotherapy for Follicular Lymphoma Using Genetically Modified CD20-Specific CD8+ Cytotoxic T Lymphocytes"],"prefix":"10.1016","volume":"9","author":[{"given":"Jinjuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver W","family":"Press","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine G","family":"Lindgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley","family":"Riddell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Laugen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Raubitschek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J","family":"Forman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael C","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2003.12.011_BIB1","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12<2311::AID-CNCR13>3.0.CO;2-X","article-title":"The national cancer database report on non-Hodgkin's lymphoma","volume":"80","author":"Glass","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ymthe.2003.12.011_BIB2","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood.V69.2.584.584","article-title":"Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B-cell lymphomas","volume":"69","author":"Press","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2003.12.011_BIB3","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJM199310213291702","article-title":"Radiolabeled-antibody therapy of B lymphoma with autologous bone marrow support","volume":"329","author":"Press","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2003.12.011_BIB4","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2BB: Results of a Phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2003.12.011_BIB5","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2BB: (Rituximab) Anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2003.12.011_BIB6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1040-8428(01)00130-5","article-title":"Rituximab: perspective on single agent experience, and future directions in combination trials","volume":"40","author":"McLaughlin","year":"2001","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ymthe.2003.12.011_BIB7","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"Mclaughlin","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2003.12.011_BIB8","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1008389119525","article-title":"Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma","volume":"10","author":"Piro","year":"1999","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ymthe.2003.12.011_BIB9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1365-2141.2000.01965.x","article-title":"A UK multicentre Phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response","volume":"109","author":"Foran","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ymthe.2003.12.011_BIB10","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1200\/JCO.1999.17.6.1851","article-title":"Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a Phase II trial of rituximab","volume":"17","author":"Davis","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2003.12.011_BIB11","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","article-title":"Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy","volume":"17","author":"Czuczman","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2003.12.011_BIB12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1634\/stemcells.20-3-215","article-title":"Cell surface antigen and molecular targeting in the treatment of hemotologic malignancies","volume":"20","author":"Countouriotis","year":"2002","journal-title":"Stem Cells"},{"key":"10.1016\/j.ymthe.2003.12.011_BIB13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1535-6108(03)00113-2","article-title":"Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction","volume":"3","author":"Ho","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2003.12.011_BIB14","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1172\/JCI0217214","article-title":"Adoptive therapy with CD8+ T cells: it may get by a little help from its friends","volume":"110","author":"Ho","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2003.12.011_BIB15","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0264-410X(02)00598-4","article-title":"Tumor antigen-specific T cells and cancer immunotherapy: current issues and future prospects","volume":"21","author":"Kalos","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2003.12.011_BIB16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1517\/14712598.2.1.55","article-title":"Adoptive T cell therapy for the treatment of solid tumors","volume":"2","author":"Knutson","year":"2002","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ymthe.2003.12.011_BIB17","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with anti-tumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2003.12.011_BIB18","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V92.5.1549.417k32_1549_1555","article-title":"Infusion of cytotoxic T cells for the prevention and treatment of Epstein\u2013Barr virus-induced lymphoma in allogeneic transplant recipients","volume":"92","author":"Rooney","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2003.12.011_BIB19","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood.V91.8.2925.2925_2925_2934","article-title":"Epstein\u2013Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease","volume":"91","author":"Roskrow","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2003.12.011_BIB20","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm0596-551","article-title":"Long-term restoration of immunity against Epstein\u2013Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes","volume":"2","author":"Heslop","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2003.12.011_BIB21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/146532402317251491","article-title":"Clinical trials with CMV-specific T cells","volume":"4","author":"Peggs","year":"2002","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2003.12.011_BIB22","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","article-title":"Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T cell clones from the donor","volume":"333","author":"Walter","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2003.12.011_BIB23","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1126\/science.1352912","article-title":"Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones","volume":"257","author":"Riddell","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2003.12.011_BIB24","doi-asserted-by":"crossref","first-page":"16168","DOI":"10.1073\/pnas.242600099","article-title":"Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patient with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells","volume":"99","author":"Yee","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2003.12.011_BIB25","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1096\/fasebj.6.15.1464371","article-title":"Endowing T cells with antibody specificity using chimeric T cell receptors","volume":"6","author":"Gross","year":"1992","journal-title":"FASEB J."},{"key":"10.1016\/j.ymthe.2003.12.011_BIB26","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxicity lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2003.12.011_BIB27","doi-asserted-by":"crossref","first-page":"6577","DOI":"10.4049\/jimmunol.151.11.6577","article-title":"Targeting of T lymphocytes to Neu\/HER2-expressing cells using chimeric single chain Fv receptors","volume":"151","author":"Stancovski","year":"1993","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2003.12.011_BIB28","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1073\/pnas.91.10.4318","article-title":"Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells","volume":"91","author":"Moritz","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2003.12.011_BIB29","first-page":"3369","article-title":"In vivo antitumor activity of T cells redirected with chimeric antibody\/T cell receptor genes","volume":"55","author":"Hwu","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2003.12.011_BIB30","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nm827","article-title":"Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15","volume":"3","author":"Brentjens","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2003.12.011_BIB31","doi-asserted-by":"crossref","first-page":"836","DOI":"10.4049\/jimmunol.157.2.836","article-title":"Single chain Ig\/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity","volume":"157","author":"Weijtens","year":"1996","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2003.12.011_BIB32","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1042\/bst0231079","article-title":"Chimeric T-cell receptors specific to a B-lymphoma idiotype: a model for tumor immunotherapy","volume":"23","author":"Gross","year":"1995","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ymthe.2003.12.011_BIB33","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1053\/bbmt.1998.v4.pm9763110","article-title":"CD20 is a molecular target for scFvFc: \u03b6 receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy","volume":"4","author":"Jensen","year":"1998","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ymthe.2003.12.011_BIB34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1006\/mthe.1999.0012","article-title":"Human T lymphocyte genetic modification with naked DNA","volume":"1","author":"Jensen","year":"2000","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2003.12.011_BIB35","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/14653240310001028","article-title":"Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy","volume":"5","author":"Jensen","year":"2003","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2003.12.011_BIB36","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1182\/blood.V89.10.3806","article-title":"Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro","volume":"89","author":"Schultze","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2003.12.011_BIB37","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.4049\/jimmunol.171.4.2134","article-title":"Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common gamma-chain cytokines","volume":"171","author":"Anichini","year":"2003","journal-title":"J. Immunol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001603004155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001603004155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:45:45Z","timestamp":1778816745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001603004155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["S1525001603004155"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2003.12.011","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cellular Immunotherapy for Follicular Lymphoma Using Genetically Modified CD20-Specific CD8+ Cytotoxic T Lymphocytes","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2003.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}